<DOC>
	<DOCNO>NCT01807520</DOCNO>
	<brief_summary>To demonstrate efficacy secukinumab versus placebo nail psoriasis ass long-term efficacy , safety tolerability secukinumab .</brief_summary>
	<brief_title>Study Safety , Tolerability , Efficacy Secukinumab Subjects With Moderate Severe Nail Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Subjects chronic moderate severe plaque type psoriasis least 6 month prior randomization , include significant nail involvement , define Nail Psoriasis Severity Index ( NAPSI ) score ≥16 AND number fingernail involve ≥4 AND Psoriasis Area Severity Index ( PASI ) score ≥12 AND Body Surface Area ( BSA ) score ≥10 % Candidates systemic therapy , i.e . psoriasis inadequately control topical treatment ( include super potent topical corticosteroid ) and/or phototherapy and/or previous systemic therapy Forms psoriasis chronic plaque type psoriasis ( e.g. , pustular psoriasis , palmoplantar pustulosis , acrodermatitis Hallopeau , erythrodermic guttate psoriasis ) Druginduced psoriasis ( e.g . new onset current exacerbation βblockers , calcium channel inhibitor lithium ) Ongoing inflammatory skin diseases psoriasis disease affect fingernail may potentially confound evaluation study treatment effect Ongoing use prohibit treatment ( e.g . topical systemic corticosteroid ( CS ) , UV therapy ) . Washout period apply Prior exposure secukinumab ( AIN457 ) biological drug directly target IL17 IL17 receptor Exposure investigational drug within 4 week prior study treatment initiation within period 5 halflives investigational treatment , whichever long History hypersensitivity constituent study treatment Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Moderate nail psoriasis</keyword>
	<keyword>Severe nail psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Secukinumab</keyword>
</DOC>